Editorial Board

The Journal of OncoPathology - Information for Contributors

Submission Preparation Checklist and Technical Requirements
Technical and stylistic requirements
Images and Tables
General information for authors
Types of articles accepted
Manuscript selection
Submission requirements and conditions of acceptance
Author Fees
Embargo Policy
Publication Ethics Policies for the Journal of OncoPathology
           Study design and ethics
           Supplementary data
           Authorship
           Peer review process
           Editorial decisions
           Appeal
           Originality, prior publication, and media relations
           Plagiarism policy
           Responding to allegations of possible misconduct
           Responses to possible misconduct
           Corrections


As part of the submission process, authors are required to check off their submission’s compliance with all of the following items.
The submission has not been previously published, nor is it before another journal for consideration.
(1) The submission file is in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format.
(2) Where available, URLs for the references should be provided.
(3) The text is single spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
(4) The text adheres to the stylistic and bibliographic requirements outlined below.

Technical and stylistic requirement
Manuscripts should be prepared concisely in clear and grammatically correct English and should contain:
(1) A title page with article type (eg, Review, Original, Case Report, Research, etc.).
(2) An abstract of up to 250 words plus up to seven further keywords for indexing purposes. Abstracts are also required for review articles. The abstract should be self-contained and citation-free.
(3) Text containing the introduction, materials and methods, results, discussion, acknowledgments, and references.
(4) Figure legends.
(5) Footnotes.
(6) Tables (with descriptive titles and legends).
(7) Referencing.
(8) Declaration of conflict of interest and funding disclosure.
(9) Declaration of contributions each author has made to the article.
(10) For reports containing original data, at least one author should indicate that she or he had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
(11) Manuscripts must use the Vancouver (author-number) style of referencing; that is, a number series to indicate references. The references must then list these in numerical order as they appear in the text.
(12) The manuscript title must be descriptive and must not contain any brand names. Drugs must be identified by their generic name.
(13) The manuscript should conform to the standard detailed in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (http://www.icmje.org). Please use US-English spelling for the final edit of a manuscript. All measurements must be given in the International System of units (SI) (meters, kilograms, seconds, etc.).

Images and tables
Tables and charts should complement the text as opposed to duplicate it. Photographs and illustrations must be supplied in high resolution, at least 300 dpi JPEG/tiff format.
It is the authors’ responsibility to obtain permissions from the concerned publishers/institutions for the reproduction or reuse of figures, tables, and other materials.

General information for authors
The Journal of OncoPathology seeks to publish those papers that are most influential in their fields or across fields and that will significantly advance scientific understanding and clinical practice. Selected papers should present novel and broadly important data, syntheses, or concepts.

Types of articles accepted
(1) Research articles and Original reports (up to ~3500 words, including references, notes, and captions) are expected to present a major advance. Materials and methods should usually be included in supplementary materials, which should also include information needed to support the paper’s conclusions.
(2) Review article (up to 4500 words including references, notes, and captions) describes new developments, summarizes progress or collects published evidence for analysis.
(4) Commentary section present analysis or opinions on issues of interest in oncology/pathology.
(3) Perspectives/Editorials (up to 1000 words plus one figure) highlight recent exciting research, but do not primarily discuss the author’s own work. They may provide context for the findings within a field or explain potential interdisciplinary significance. Perspectives commenting on papers in the Journal of OncoPathology should add a dimension to the research and not merely be a summary of the experiments done in the paper. Although many of the Perspectives that comment on research published in the Journal of OncoPathology are solicited, we welcome inquiries regarding new advances and fresh insights. As these are meant to express a personal viewpoint, with rare exceptions, Perspectives should have no more than two authors.
(5) Case Reports (up to ~1500 words, including references, notes, and captions) present unreported or unusual events in oncology pathology. Include a brief overview describing the case and a concise literature review. Do not include an abstract. Please describe figures in the text rather than in separate legends. All identifying information of patients, such as names, dates of birth, dates of service, or patient identification codes must be removed. If the case report or the image includes individually identifiable health information, authors must comply with the applicable privacy laws and obtain a patient authorization form.
(6) Books et al. (up to 1000 words) presents reviews of current books, multimedia, exhibitions, and films of interest in oncology/pathology.
(7) Policy Forum (1000–2000 words plus 1–2 figures) presents issues related to the intersections between the Journal of OncoPathology and society that have policy implications.
(8) Education Forum (approximately 2000 words) presents essays on the Journal of OncoPathology education and its practice from pre-college to graduate work. They are not meant to be research reports of an individual program. (Research results related to education should be submitted to the Reports section.)
(9) Letters (up to 300 words) discuss material published in the Journal of OncoPathology in the last three months or issues of general interest.
(10) Comments: brief online comments can be submitted on papers or news stories published in the Journal of OncoPathology immediately after publication. Comments are submitted from the full-text view on the Journal of OncoPathology online and will be evaluated promptly and if accepted, posted with the article.
(11) Technical Comments (up to 1000 words, 2 figures or tables, and 15 references) are published in full on the Journal of OncoPathology online and discuss research papers published in the Journal of OncoPathology within the previous three months. Authors should submit a brief abstract (60 words or less) to accompany their comment that will be included in the Letters section of the print edition. Technical Comments should not normally contain supplementary materials. Contents of Technical Comments posted elsewhere, in print or online, including on preprint servers, will generally not be considered.
Technical Comments will be considered if they address the core conclusions and/or core methodology of a Journal of OncoPathology paper. They may repeat the experiments and observations of the paper but they should not otherwise contain new data or other previously unpublished work. They should not be based on new findings/concepts that would not have been accessible to the authors when the paper was written. Pertinent comments and observations on noncentral aspects of a paper should instead be posted in online comments associated with each paper.
Authors of Technical Comments should contact the authors of the paper before submitting their Technical Comment to the Journal of OncoPathology, and submit to the Journal of OncoPathology the evidence of any correspondence between them. Technical Comments may be peer-reviewed at the editors’ discretion. We hope to post these online along with a formal reply from the authors of the original paper

SPECIAL ARTICLES
(1) How I Treat/How I diagnose (up to 4500 words including references, notes and captions) is a special article type in the Journal of OncoPathology. It provides a comprehensive approach to the diagnosis, classification, and treatment of patients, with particular attention to differential diagnosis, subclassification of patients, the tools plus technologies employed to aid treatment selection, planning, the therapeutics used, how the clinicians overcome resistance, and achieve a continuum of care. The considerations and recommendations are intended to be practical and relevant for oncologists, pathologists, and associated physicians involved in the care of patients, with the ultimate goal of improving diagnosis, treatment and outcomes.
(2) Where does it fit? (up to 4500 words including references, notes and captions), when preparing this article type please consider addressing issues including the agents mechanism of action, pharmacokinetics, safety, pharmacodynamics, and efficacy. Please also review key preclinical and clinical studies for the agent for this cancer, the data for the agent placed in the context of the changing landscape of therapeutic options for this cancer, relevant ongoing clinical trials and future directions plus your own expert opinion on how this agent might become integrated into routine clinical management for this cancer. Additional topics which you might consider using the manuscript to address are the agent as a monotherapy versus combination therapy, best dosing strategy, how long to give treatment, the role of predictive biomarkers, potential pharmacodynamic markers, the possible role and benefit of the agent in light of the other approved agents, who is the ideal patient for this agent?

Manuscript selection
The Journal of OncoPathology is committed to prompt evaluation and publication of submitted papers. Manuscripts and Letters to the Editor for the Journal of OncoPathology should be submitted online. Please follow the formatting instructions and uploading directions found on this site.
The Journal of OncoPathology treats all submitted manuscripts as confidential documents. Our peer review process is also confidential and identities of reviewers are not released.
Papers are assigned to a staff editor who has knowledge of the field discussed in the manuscript. Most submitted papers are rated for suitability by members of the Journal of OncoPathology’s Board of Reviewing Editors. The editors at the Journal of OncoPathology consider this advice in selecting papers for in-depth review. Authors of papers that are not selected are notified promptly, within about two weeks.
Research papers that are selected for in-depth review are evaluated by at least two outside referees. Reviewers are contacted before being sent a paper and asked to return comments within 1–2 weeks for most papers. We are able to expedite the review process significantly for papers that require rapid assessment. Selected papers are edited to improve accuracy and clarity and for length. Papers cannot be resubmitted over a disagreement on novelty, interest or relative merit. If a paper was rejected on the basis of serious reviewer error, resubmission may be considered.

Submission requirements and conditions of acceptance
(1) AUTHORSHIP; All authors must agree to be so listed and must have seen and approved the manuscript, its content, and its submission to the Journal of OncoPathology. The Journal of OncoPathology will send an email to all authors to confirm receipt of each paper. Submission of a paper that has not been approved by all authors may result in immediate rejection without appeal. Any changes in authorship must be approved in writing by all the original authors. All authors of accepted manuscripts are required to affirm and explain their contribution to the manuscript, agree to the conditions of publication including the availability of data and materials, and declare any conflicts of interest. The senior author from each group is required to have examined the raw data their group has produced. Specific information will be sent to most authors at the time of manuscript revision.
(2) FUNDING AND CONFLICT OF INTEREST; Authors must agree to disclose all affiliations, funding sources, and financial or management relationships that could be perceived as potential sources of bias, as defined by the Journal of OncoPathology’s conflict of interest policy.
(3) PRIOR PUBLICATION; The Journal of OncoPathology will not consider any paper or component of a paper that has been published or is under consideration for publication elsewhere. Distribution on the Internet may be considered prior publication and may compromise the originality of the paper as a submission to the Journal of OncoPathology. Please contact the editors with questions regarding allowable postings. Prior press coverage reports of the main findings of a paper in the mass media may compromise the novelty of the work and thus its appropriateness for the Journal of OncoPathology. Authors are free to present their work at scientific meetings but should not overtly seek media attention or give copies of the figures or data from their manuscript to any reporter, unless the reporter agrees to abide by the Journal of OncoPathology’s press embargo. If a reporter attends an author’s session at a meeting and writes a story based only on the presentation, such coverage will not affect the Journal of OncoPathology’s consideration of the author’s paper.
(4) UNPUBLISHED DATA AND PERSONAL COMMUNICATIONS; Citations to unpublished data and personal communications cannot be used to support claims in a published paper. Papers will be held for publication until all “in press” citations are published.
(5) DATA AND MATERIALS AVAILABILITY; All data necessary to understand, assess, and extend the conclusions of the manuscript must be available to any reader of the Journal of OncoPathology. All computer codes involved in the creation or analysis of data must also be available to any reader of the Journal of OncoPathology.
(6) HUMAN RESEARCH STUDIES; Informed consent must be obtained for studies on humans after the nature and possible consequences of the studies were explained. All research on humans must have Institutional Review Board approval.
(7) ANIMAL CARE EXPERIMENTAL; Animals must be handled in accordance with the authors’ institutional guidelines.
(8) LICENSE; Authors grant to the Journal of OncoPathology a license to publish the paper in print and online.

Author Fees
The Journal of OncoPathology charges an article publication fee of €900.00. If this paper is accepted for publication, you will be asked to pay an Article Publication Fee to cover publications costs. If you do not have funds to pay such fees, you will have an opportunity to waive or reduce this fee as we do not want fees to prevent the publication of worthy work. Invited papers are exempt from this fee.

Embargo Policy
The paper will remain a privileged document and will not be released to the press or the public before publication.

Publication Ethics Policies for the Journal of OncoPathology
           Study design and ethics
Good research should be well justified, well planned, and appropriately designed, so that it can properly address the research question. Research should be conducted to high standards of quality control and data analysis. Data and records must be retained and produced for review upon request. Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of data constitute scientific misconduct.
When reporting experiments on human subjects, indicate whether the procedures followed, were in accordance with the ethical standards of a relevant Institutional Review Board/Ethics committee or with the Helsinki Declaration of the World Medical Association. Please do not use patients’ names, initials, or hospital numbers.
All authors are required to confirm in their manuscript and cover letter if their study has been approved by their Institutional Review Board/Ethics committee. If the study is judged exempt from review, a statement from the committee is to be submitted with the cover letter and at the end of their manuscript.
When reporting experiments on animals, indicate whether the institution’s or the National Research Council’s guide for, or any national law on, the care and use of laboratory animals were followed.
Animal experiments require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements. The Journal of OncoPathology requires all authors to indicate in writing whether the institution’s or the National Research Council’s guide for, or any national law on, the care and use of laboratory animals were followed.

           Supplementary data
Supporting material that cannot be included in the printed version for reasons of space, and that is not essential for inclusion in the full text of the manuscript, but would nevertheless benefit the reader. It should not be essential to understanding the conclusions of the paper, but should contain data that are additional or complementary and directly relevant to the article content. For example, more detailed methods, extended data sets/data analysis, tables, or additional figures (including color).
All supplementary data must be submitted at the same time as the main manuscript for peer review. Please indicate clearly the material intended as supplementary data upon submission. Also ensure that the supplementary data are referred to in the main manuscript at an appropriate point in the text. It must be supplied with the article for publication, not at a later date. It cannot be altered or replaced after the paper has been accepted for publication.
Please note that supplementary data will not be edited, so ensure that it is clearly and succinctly presented, and that the style of terms conforms with the rest of the paper. Also ensure that the presentation will work on any internet browser.
          Acceptable formats; A maximum of 10 files is acceptable to make up the supplementary data unit for an article. The maximum size per file should not exceed 1.5 MB. Please provide short titles for each individual file.
Recommendations:
(1) Provide text files in PDF (.pdf), MS Word (.doc) or RTF (.rtf) format. (2) Provide spreadsheet files in MS Excel (.xls) or CSV format.
(3) Provide image files in tiff, gif or jpg format. Images should be a maximum size of 640 × 480 pixels (9 × 6.8 inches at 72 pixels per inch minimum resolution).
(4) Provide sound clips in mp3 format.
(5) Provide movie clips in mpeg format.

           Authorship
The Journal of OncoPathology adheres to the guidelines on authorship established by the International Committee of Medical Journal Editors statement on Authorship and Contribution. According to these guidelines, the criteria established for authorship are intended to present an honest account of what took place. Those with substantial intellectual contributions or who have written the manuscript should be included as an author.
If someone other than the authors, such as a science writer or corporate employee, has participated in writing the paper, this participation must be disclosed. If a multicenter group conducted the research, the group should identify a writing committee that accepts direct responsibility for the manuscript.
For all manuscripts, the corresponding author is required to provide information on the specific contributions that each author has made to the article, please note that this description of author contributions is printed with the article. All authors are responsible for the quality, accuracy, and ethics of the work. If writers are provided by the sponsoring or funding institution or corporation to draft or revise the article, the name of the writer and their sponsoring organization must be provided.
For reports containing original data, at least one author (eg, the principal investigator) should indicate that she or he had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

           Peer review process
The Journal of OncoPathology employs a double-blind review process, so authors do not know the identity of the reviewers and vice-versa. The Journal of OncoPathology editors solicit reviewers using a database of experts, the majority of whom are Editorial Board members of the Journal of OncoPathology. These reviewers provide comments for the editors and the authors, as well as a recommendation on the decision. Upon receiving the comments, the editor assigned to the manuscript will ultimately make the decision. The editor-in-chief approves all accept and reject decisions.
Upon completion of review, the editor’s decision will be e-mailed to the corresponding author, along with instructions for accessing the reviewers’ comments online. The author will receive one of the following decisions.

REJECT; The editors did not select your manuscript for publication. Many factors contribute to acceptance including, but not limited to, the following:
Importance of the research to the field of oncology.
The originality of the work.
The quality of the study.
The priority of the work to the Journal of OncoPathology and its readership.
MAJOR REVISION; The editors believe that your article contained information of potential importance but a number of major issues were raised. If you believe that you can address the issues raised, the editors would be willing to reconsider your manuscript, but cannot guarantee acceptance, particularly if you cannot address the concerns.
MINOR REVISION; The editors found your manuscript potentially acceptable for publication provided you make some minor adjustments.
ACCEPTANCE; The editors selected your manuscript for publication. Additional information will be provided regarding embargo policies and the production process.

As of April 2013, 87% of all submitted papers were sent out for external peer review, 25% of submissions were accepted for publication.
tJOP publishes annual audits of acceptance rates, publication intervals, percentage of submissions sent out for external peer review, and other performance data. Authors may expect to learn of rejection or acceptance in approximately two weeks, depending on the turnaround time for reviews.

           Editorial decisions
Decisions about a manuscript are entirely based only on its importance, originality, clarity, and relevance to the journal’s scope and content. Studies with negative results despite adequate power, or those challenging previously published work, receive equal consideration.

           Appeal
If an author disagrees with the editorial decision, cordial inquiry is invited through the online manuscript processing system. The response must be timely and include a detailed rebuttal.

           Originality, prior publication, and media relations
PRIOR PUBLICATION; The Journal of Oncopathology will not consider any paper or component of a paper that has been published or is under consideration for publication elsewhere. Distribution on the Internet may be considered prior publication and may compromise the originality of the paper as a submission to the Journal of Oncopathology. Please contact the editors with questions regarding allowable postings.
PRIOR PRESS; Coverage reports of the main findings of a paper in the mass media may compromise the novelty of the work and thus its appropriateness for the Journal of Oncopathology. Authors are free to present their work at scientific meetings but should not overtly seek media attention or give copies of the figures or data from their manuscript to any reporter, unless the reporter agrees to abide by the Journal of Oncopathology’s press embargo. If a reporter attends an author’s session at a meeting and writes a story based only on the presentation, such coverage will not affect the Journal of Oncopathology’s consideration of the author’s paper.
Previous publication of an abstract during the proceedings of meetings (in print or electronically) does not preclude subsequent submission for publication, but full disclosure should be made at the time of submission.
EMBARGO POLICY; The paper will remain a privileged document and will not be released to the press or the public before publication.

           Plagiarism policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible editor(s).

           Responding to allegations of possible misconduct
To help protect the integrity of the public scientific record, the Journal of OncoPathology will share reasonable concerns with relevant authorities, allegations of possible misconduct including:
                    • Falsification of data
                    • Plagiarism
                    • Improprieties of authorship
                    • Misappropriation of the ideas of others
                    • Violation of generally accepted research practices
                    • Material failure to comply with legislative and regulatory requirements affecting research
                    • Inappropriate behavior in relation to misconduct.

           Responses to possible misconduct
All allegations of misconduct will be referred to the editor-in-chief, who will review the circumstances in consultation with the deputy editors. Initial fact-finding will usually include a request to all the involved parties to state their case, and explain the circumstances, in writing. In questions of research misconduct centering on methods or technical issues, the editor-in-chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside editor expert. The editor-in-chief and deputy editors will arrive at a conclusion as to whether there is enough evidence to lead a reasonable person to believe there is a possibility of misconduct. Their goal is not to determine if actual misconduct occurred, or the precise details of that misconduct.
When allegations concern authors, the peer review and publication process for the manuscript in question will be halted while the process above is carried out. The investigation described above will be completed even if the authors withdraw their paper, and the responses below will still be considered. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.
All such allegations are kept confidential; the number of inquiries and those involved should be kept to the minimum necessary to achieve this end. Whenever possible, references to the case in writing should be kept anonymous.
The Journal of OncoPathology has an obligation to readers and patients to ensure that their published research is both accurate and adheres to the highest ethical standard. Therefore, if the inquiry concludes there is a reasonable possibility of misconduct, responses should be undertaken, chosen in accordance with the apparent magnitude of the misconduct. Responses may be applied separately or combined, and their implementation should depend on the circumstances of the case as well as the responses of the participating parties and institutions. The following options are ranked in approximate order of severity:

                    • A letter of explanation (and education) sent only to the person against whom the complaint is made, where there appears to be a genuine and innocent misunderstanding of principles or procedure.
                    • A letter of reprimand to the same party, warning of the consequences of future such instances, where the misunderstanding appears to be not entirely innocent.
                    • A formal letter as above, including a written request to the supervising institution that an investigation be carried out and the findings of that inquiry reported in writing to the journal.
                    • Publication of a notice of redundant or duplicate publication or plagiarism, if appropriate (and unequivocally documented). Such publication will not require approval of authors, and will also be reported to their institution.
                    • Formal withdrawal or retraction of the paper from the scientific literature, published in the journal, informing readers and the indexing authorities (National Library of Medicine, etc.), if there is a formal finding of misconduct by an institution. Such publication will not require approval of authors, will also be reported to their institution, and will be readily visible in the Journal of OncoPathology.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the journal, and this fact reported to their institution.

           Corrections
If a published paper is subsequently found to have errors or major flaws, the editor will issue a correction in the next available edition of the Journal of OncoPathology. The specific content of the correction may address whether the errors originated with the author or the journal. The correction will be listed in the table of contents to ensure that it is linked to the article to which it pertains in public databases such as PubMed.